NONOF - Novo Nordisk CEO wins 13% raise amid soaring demand for weight loss drugs
2024-02-07 13:52:09 ET
More on Novo Nordisk
- Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript
- Biotech And Pharma Diversification Pays Off
- Novo Nordisk: Outlook For Weight Loss Drugs In 2024
- Lilly reportedly worried about impact of Catalent/Novo deal
- Novo-Catalent deal to ease Wegovy supply concerns